Multiple FDA User Fee Policies Complicate Combo Product Review Process
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of combination products should not be required to submit two separate filings to FDA, in part because of practical questions concerning user fee collection across the agency's centers, Wyeth Associate Director-Regulatory Affairs Owen Fields, PhD, said during FDA's public meeting on combination products Nov. 25
You may also be interested in...
Baxter Urges OCP Review Panel For Jurisdictional Assignment
Consultative reviews for combination products should be linked to review division goals as an incentive for completing timely consults, American Medical Systems recommends
Baxter Urges OCP Review Panel For Jurisdictional Assignment
Consultative reviews for combination products should be linked to review division goals as an incentive for completing timely consults, American Medical Systems recommends
Wyeth BMP-2 Should Be Limited To “Problem” Fractures – Panel
Wyeth's InductOs recombinant human bone morphogenic protein-2 indications for use should be limited to "problem" fractures, according to FDA's Orthopaedic and Rehabilitation Devices Panel